JP2020500163A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500163A5
JP2020500163A5 JP2019521018A JP2019521018A JP2020500163A5 JP 2020500163 A5 JP2020500163 A5 JP 2020500163A5 JP 2019521018 A JP2019521018 A JP 2019521018A JP 2019521018 A JP2019521018 A JP 2019521018A JP 2020500163 A5 JP2020500163 A5 JP 2020500163A5
Authority
JP
Japan
Prior art keywords
ala
controlled release
gly
preparation
release preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019521018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500163A (ja
JP7626362B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/057606 external-priority patent/WO2018075901A1/en
Publication of JP2020500163A publication Critical patent/JP2020500163A/ja
Priority to JP2023016292A priority Critical patent/JP2023065401A/ja
Publication of JP2020500163A5 publication Critical patent/JP2020500163A5/ja
Application granted granted Critical
Publication of JP7626362B2 publication Critical patent/JP7626362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019521018A 2016-10-20 2017-10-20 中枢神経系に神経保護ポリペプチドを送達する方法 Active JP7626362B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023016292A JP2023065401A (ja) 2016-10-20 2023-02-06 中枢神経系に神経保護ポリペプチドを送達する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410748P 2016-10-20 2016-10-20
US62/410,748 2016-10-20
PCT/US2017/057606 WO2018075901A1 (en) 2016-10-20 2017-10-20 Methods of delivering a neuroprotective polypeptide to the central nervous system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023016292A Division JP2023065401A (ja) 2016-10-20 2023-02-06 中枢神経系に神経保護ポリペプチドを送達する方法

Publications (3)

Publication Number Publication Date
JP2020500163A JP2020500163A (ja) 2020-01-09
JP2020500163A5 true JP2020500163A5 (enExample) 2024-11-28
JP7626362B2 JP7626362B2 (ja) 2025-02-07

Family

ID=60382598

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019521018A Active JP7626362B2 (ja) 2016-10-20 2017-10-20 中枢神経系に神経保護ポリペプチドを送達する方法
JP2023016292A Pending JP2023065401A (ja) 2016-10-20 2023-02-06 中枢神経系に神経保護ポリペプチドを送達する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023016292A Pending JP2023065401A (ja) 2016-10-20 2023-02-06 中枢神経系に神経保護ポリペプチドを送達する方法

Country Status (12)

Country Link
US (2) US11273130B2 (enExample)
EP (2) EP3528836A1 (enExample)
JP (2) JP7626362B2 (enExample)
KR (2) KR102687778B1 (enExample)
CN (1) CN110191717A (enExample)
AU (1) AU2017345724B2 (enExample)
BR (1) BR112019008021A2 (enExample)
CA (1) CA3040906A1 (enExample)
MX (1) MX2019004476A (enExample)
SG (1) SG11201903462UA (enExample)
WO (1) WO2018075901A1 (enExample)
ZA (1) ZA201902486B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102687778B1 (ko) 2016-10-20 2024-07-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신경 보호 폴리펩티드를 중추 신경계에 전달하는 방법
CN114206374A (zh) * 2019-07-29 2022-03-18 佩特通公司 用于治疗左旋多巴诱导的运动障碍或用于抑制其进展的药物组合物
MX2022001121A (es) 2019-07-29 2022-02-16 Peptron Inc Composicion farmaceutica para el tratamiento de la disquinesia inducida por levodopa o para la supresion de la progresion de la misma.
EP4153214A4 (en) 2020-05-22 2024-06-26 Trustees of Boston University Methods and compositions for treating a fibrotic disease
CN112014193B (zh) * 2020-07-24 2021-06-15 武汉大学中南医院 一种新的fj染色方法和装置
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN116392576A (zh) * 2023-05-26 2023-07-07 南通大学 一种gip受体激动剂在制备治疗脊髓损伤修复靶点药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
DE69720190T2 (de) 1996-02-02 2003-12-11 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
CA2309356C (en) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
CA2315890C (en) 1997-12-22 2009-08-11 Alza Corporation Rate controlling membranes for controlled drug delivery devices
EP1041968B1 (en) 1997-12-29 2004-03-03 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
ATE342051T1 (de) 1997-12-30 2006-11-15 Alza Corp Verabreichungssystem für wirkstoffe mit einem membranstöpsel
DE69906132T2 (de) 1998-12-31 2003-12-18 Alza Corp., Mountain View Osmotisches verabreichungsystem mit raumsparenden kolben
AU773354B2 (en) 1999-12-21 2004-05-20 Intarcia Therapeutics, Inc. Valve for osmotic devices
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
WO2004002565A1 (en) 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7207982B2 (en) 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US9259432B1 (en) * 2011-01-31 2016-02-16 Parminder J. S. Vig Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
JP6226510B2 (ja) 2012-01-27 2017-11-08 キヤノン株式会社 画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it) 2013-03-05 2014-09-06 Telecom Italia Spa Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
JP2015192425A (ja) 2014-03-28 2015-11-02 富士通株式会社 デマンド収容変更順序決定方法、およびデマンド収容変更順序決定プログラム
EP3132790A4 (en) * 2014-04-16 2017-11-22 Shandong Luye Pharmaceutical Co., Ltd. Exenatide-containing composition and preparation method therefor
KR102687778B1 (ko) 2016-10-20 2024-07-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신경 보호 폴리펩티드를 중추 신경계에 전달하는 방법

Similar Documents

Publication Publication Date Title
EP2134329B1 (en) Composition and microsphere for controlled-release of exendin, and method of preparing the same
ES2552646T3 (es) Exendinas para disminuir el colesterol y los triglicéridos
Lacroix et al. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations
CA2320371A1 (en) Inotropic and diuretic effects of exendin and glp-1
JP7626362B2 (ja) 中枢神経系に神経保護ポリペプチドを送達する方法
US20020055496A1 (en) Formulation and system for intra-oral delivery of pharmaceutical agents
JP2002500193A (ja) 単量体インシュリンアナログの投与方法
CN101588789B (zh) 用于治疗牛和其它动物炎症的药物组合物和方法
MX2008016254A (es) Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia.
WO2003004031A1 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
AU2002318211A1 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
Minchin et al. Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs
WO2022046976A1 (en) An epinephrine injection formulation with very low epinephrine concentration and low impurities during its shelf-life
Desai et al. Nanotechnology-based mucoadhesive and mucus-penetrating drug-delivery systems for transbuccal drug delivery
WO2019193417A1 (en) Composition and method of reducing joint pain associated with hemarthrosis
US20120190618A1 (en) Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type ii diabetes
Ramsay Pharmacokinetics and clinical use of parenteral phenytoin, phenobarbital, and paraldehyde
US20050004221A1 (en) Intrathecal gabapentin compositions
JP2021512061A (ja) ウリジンの全身送達のための組成物及びデバイス
US20140377365A1 (en) Sustained-release formulation of rotigotine
CN121773127A (zh) 用于治疗人类疾病和病症的稳定glp-1类似物
JP7518149B2 (ja) 高濃度インスリン製剤
Demmy et al. Resuscitation of injured myocardium with adenosine and biventricular assist
KR20170099911A (ko) 파라세타몰 주사 제제
EP1682149B1 (en) Injectable gabapentin compositions